Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

作者
Lajos Géczi,G. Bodoky,György Rokszin,Ibolya Fábián,László Torday
出处
期刊:Pathology & Oncology Research [Springer Science+Business Media]
卷期号:26 (4): 2201-2207 被引量:9
标识
DOI:10.1007/s12253-020-00809-z
摘要

BACKGROUND: Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma (mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence comparing sequencing strategies, and available comparative data regarding the real-world effectiveness of different therapeutic sequences are limited. MATERIALS AND METHODS: We identified mRCC patients who initiated targeted therapy between January 1, 2008 and May 31, 2017 from the National Health Insurance Fund (NHIF) database of Hungary. Overall survival (OS) and duration of first-line treatment (DFT) were obtained for patients receiving sunitinib-everolimus, sunitinib-axitinib, or pazopanib-everolimus treatment sequences. OS of sunitinib-everolimus and sunitinib-axitinib sequences was also determined for patients having better or worse response to sunitinib first-line therapy. RESULTS: Median OS was significantly longer among patients treated with sunitinib-axitinib compared to those receiving sunitinib-everolimus. Median DFT was also significantly longer in the sunitinib-axitinib vs. sunitinib-everolimus group. Sunitinib-axitinib was associated with significantly longer median OS compared to sunitinib-everolimus in patients with better response to first-line sunitinib in the pooled sunitinib population. In patients with worse response to sunitinib, sunitinib-axitinib was associated with a trend towards greater OS compared to sunitinib-everolimus, but the difference did not reach statistical significance. CONCLUSIONS: In this nationwide database analysis, mRCC patients treated with the sunitinib-axitinib sequence had significantly longer OS compared to those receiving sunitinib-everolimus therapy. The OS benefits of second-line axitinib were consistent among patients with better response to sunitinib defined by DFT values.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ChiDaiOLD完成签到,获得积分10
刚刚
CodeCraft的应助被小蝉宝采纳,获得10
刚刚
阔达的夜山完成签到,获得积分10
1秒前
文淇完成签到,获得积分20
1秒前
Mark完成签到,获得积分10
1秒前
白糖完成签到,获得积分10
1秒前
1秒前
xf完成签到,获得积分10
2秒前
Dave完成签到,获得积分10
2秒前
梅梅王完成签到,获得积分10
2秒前
leo_zjm完成签到,获得积分10
2秒前
kingnb完成签到,获得积分10
2秒前
靓靓鱼发布了新的文献求助10
2秒前
lejunia完成签到 ,获得积分10
3秒前
小志完成签到,获得积分10
3秒前
小王发布了新的文献求助10
3秒前
重要的如霜完成签到,获得积分10
3秒前
水瓶毛毛完成签到,获得积分10
4秒前
放手一搏发布了新的文献求助30
4秒前
5秒前
快乐十一发布了新的文献求助10
5秒前
zac完成签到,获得积分10
5秒前
Dave发布了新的文献求助10
5秒前
黄婷完成签到,获得积分10
5秒前
lulu完成签到 ,获得积分10
6秒前
小木屋完成签到,获得积分10
6秒前
wqy完成签到 ,获得积分10
6秒前
TRY完成签到,获得积分10
6秒前
uu完成签到,获得积分10
6秒前
6秒前
七天完成签到,获得积分10
6秒前
科研通AI6.2的应助被姜有明采纳,获得10
7秒前
研友_VZG7GZ的应助被Wahaha采纳,获得10
7秒前
芒硝灰完成签到,获得积分10
7秒前
沉默的依秋完成签到,获得积分10
7秒前
交个朋友完成签到 ,获得积分10
7秒前
hxhdh完成签到,获得积分10
7秒前
3129386658完成签到,获得积分10
7秒前
7秒前
博观约取_奋楫笃行完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042